Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!
news

UMG and MRC Technology collaborate to develop Alzheimer’s therapy

Posted: 28 July 2015 | Victoria White

UMG and MRC Technology are to collaborate to develop a novel therapy for neurodegenerative diseases based on antibody targeting amyloid beta peptides 4-x…

Georg-August-University Göttingen (UMG) and MRC Technology (MRCT), a UK medical research charity, have signed an exclusive license agreement for the development of a novel therapy for neurodegenerative diseases based on antibody targeting amyloid beta peptides 4-x.

The aim is to develop a therapy for Alzheimer’s Disease.

The occurence of Alzheimer’s Disease is estimated at 5% of people between 65 to 75 years of age, and at 24% of persons over the age of 85 years. It is the most frequent type of dementia in elderly people. The prevalence of Alzheimer’s disease is estimated at 2.2% among the populations of the seven major markets of USA, Japan, UK, Germany, France, Italy & Spain. The increasing aging population particularly in countries like China or Brazil will dramatically increase the total number of patients.

 

Reserve your FREE place

 


Reduce preclinical failures with smarter off-target profiling

24 September 2025 | 15:00PM BST | FREE Webinar

Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.

What you’ll learn:

  • Approaches for prioritizing follow-up studies and refining risk mitigation strategies
  • How to interpret hit profiles from binding and functional assays
  • Strategies for identifying organ systems at risk based on target activity modulation
  • How to use visualization tools to assess safety margins and compare compound profiles

Register Now – It’s Free!

 

UMG will have access to MRCT’s world-class antibody humanisation expertise

The license, negotiated by MBM ScienceBridge GmbH, the technology transfer organisation of the Georg-August-Universität Göttingen, will enable UMG to access the world-class antibody humanisation expertise of MRCT’s Centre for Therapeutics Discovery and the work of its Therapeutic Antibody Group, led by Dr David Matthews. The agreement capitalises on MRCT’s renowned capability to take lab tool compounds and turn them into clinical candidates, which will then be licensed to the pharmaceutical and biotech industry.

MRCT receives an exclusive worldwide license to the IP rights of UMG related to a novel therapeutic approach for the treatment of sporadic and familial Alzheimer’s Disease, based on a panel of unique antibodies developed by its scientist Professor Dr Thomas Bayer. MRCT and UMG will then receive downstream payments dependent on the successful development and out-licensing of the antibody. This income will be used for further research within the organisations.